Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

Cited by (982)

Items 501–600 of 982

1. H1 Hemagglutinin Priming Provides Long-Lasting Heterosubtypic Immunity against H5N1 Challenge in the Mouse Model
   Juan Manuel Carreño, Shirin Strohmeier, Ericka Kirkpatrick Roubidoux, Rong Hai, Peter Palese, Florian Krammer · 2020 · mBio
2. Self-Amplifying Pestivirus Replicon RNA Encoding Influenza Virus Nucleoprotein and Hemagglutinin Promote Humoral and Cellular Immune Responses in Pigs
   Thomas Démoulins, Nicolas Ruggli, Markus Gerber, Lisa Thomann, Thomas Ebensen, Kai Schulze, Carlos A. Guzmán, Kenneth C. McCullough · 2021 · Frontiers in Immunology
3. Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter
   Cécile A. C. M. van Els, Siri Mjaaland, Lisbeth Meyer Næss, Júlia Sarkadi, Éva Gönczöl, Karen Smith Korsholm, Jon Ulf Hansen, Jørgen de Jonge, Gideon F. A. Kersten, Jennifer Warner et al. · 2014 · Human Vaccines & Immunotherapeutics
4. The potential for a controlled human infection platform in Singapore
   Shobana Balasingam, Peter Horby, Annelies Wilder‐Smith · 2014 · Singapore Medical Journal
5. Immunity to Influenza Infection in Humans
   David J. Topham, Marta L. DeDiego, Aitor Nogales, Mark Y. Sangster, Andrea J. Sant · 2019 · Cold Spring Harbor Perspectives in Medicine
6. SARS-CoV-2 inflammation durably imprints memory CD4 T cells
   Sophie L. Gray-Gaillard, Sabrina M. Solis, Han M. Chen, Clarice Monteiro, Grace O. Ciabattoni, Marie I. Samanovic, Amber R. Cornelius, Tijaana Williams, Emilie Geesey, Miguel Rodriguez et al. · 2024 · Science Immunology
7. Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in‐depth review of mechanisms of action, failure factors, and future perspectives
   Etienne Bizot, Vincent Portet Sulla, Christelle Vauloup‐Fellous, Marie‐Anne Rameix‐Welti, Vincent Gajdos, Nabila Seddiki · 2025 · Pediatric Allergy and Immunology
8. Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19
   Maria Laura De Angelis, Federica Francescangeli, Rachele Rossi, Alessandro Giuliani, Ruggero D. Maria, Ann Zeuner · 2021 · Viruses
9. Homotypic protection against influenza in a pediatric cohort in Managua, Nicaragua
   Steph Wraith, Ángel Balmaseda, Fausto Andres Bustos Carrillo, Guillermina M. Kuan, John Huddleston, John Kubale, Roger López, Sergio Ojeda, Amy J. Schiller, Brenda López et al. · 2022 · Nature Communications
10. Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults
    Joseph E. Eiden, Carlos A. Fierro, Howard Schwartz, Mark Adams, Kimberly Ellis, Roger Aitchison, Renee Herber, Yasuko Hatta, David C. Marshall, Michael J. Moser et al. · 2022 · The Journal of Infectious Diseases
11. A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
    Carly M. Bliss, Raffael Nachbagauer, Chiara Mariottini, Frans Cuevas, Jodi Feser, Abdi Naficy, David I. Bernstein, Jeffrey T. Guptill, Emmanuel B. Walter, Francesco Berlanda Scorza et al. · 2024 · EBioMedicine
12. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein
    Maria Malm, Kirsi Tamminen, Timo Vesikari, Vesna Blazevic · 2016 · Molecular Immunology
13. Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report
    Andrew John Pollard, Robert W. Sauerwein, Marc F.D. Baay, Pieter Neels, Shobana Balasingam, Philip Bejon, Nele J. Berthels, Susan Bull, Andrew P. Catchpole, Primus Che Chi et al. · 2020 · Biologicals
14. Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection
    Yo Han Jang, Baik Lin Seong · 2020 · Expert Opinion on Drug Discovery
15. Differential Approaches for Vaccination from Childhood to Old Age
    Martina Prelog · 2012 · Gerontology
16. Distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy
    Miloje Savić, Jennifer Lynn Dembinski, Ida Laake, Olav Hungnes, Rebecca Jane Cox, Fredrik Oftung, Lill Trogstad, Siri Mjaaland · 2017 · PLoS ONE
17. Tolerance induction in memory CD4 T cells requires two rounds of antigen-specific activation
    Alexandria P. David, Frances Crawford, Paul Garside, John W. Kappler, Philippa Marrack, Megan K. L. MacLeod · 2014 · Proceedings of the National Academy of Sciences
18. Systemic and Terminal Ileum Mucosal Immunity Elicited by Oral Immunization With the Ty21a Typhoid Vaccine in Humans
    Jayaum S. Booth, Seema A Patil, Leyla J. Ghazi, Robin S. Barnes, Claire M. Fraser, Alessio Fasano, Bruce D. Greenwald, Marcelo B. Sztein · 2017 · Cellular and Molecular Gastroenterology and Hepatology
19. Systemic and respiratory T-cells induced by seasonal H1N1 influenza protect against pandemic H2N2 in ferrets
    Koen van de Ven, Femke de Heij, Harry van Dijken, José A. Ferreira, Jørgen de Jonge · 2020 · Communications Biology
20. In silico design of influenza a virus artificial epitope-based T-cell antigens and the evaluation of their immunogenicity in mice
    Sergei I. Bazhan, Денис Антонец, Ekaterina V. Starostina, T. N. Ilyicheva, Olga N. Kaplina, V. Yu. Marchenko, Olga Yu. Volkova, Anastasia Bakulina, Л. И. Карпенко · 2020 · Journal of Biomolecular Structure and Dynamics
21. Drop the Needle; A Temperature Stable Oral Tablet Vaccine Is Protective against Respiratory Viral Pathogens
    Becca A. Flitter, Molly R. Braun, Sean N. Tucker · 2022 · Vaccines
22. Pulmonary resident memory T cells in respiratory virus infection and their inspiration on therapeutic strategies
    Meng Zhang, Na Li, Yanchao He, Tianyun Shi, Zhijun Jie · 2022 · Frontiers in Immunology
23. Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus
    Wen Tzuen Heng, Hui Xuan Lim, Kuan Onn Tan, Chit Laa Poh · 2023 · Pharmaceutical Research
24. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses
    Marc P Girard, John S. Tam, Yuri Pervikov, Jacqueline M. Katz · 2013 · Vaccine
25. Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies
    Anna Roos, Ramon Roozendaal, Theeuwsen Jessica, Sarra Riahi, Joost Vaneman, Jeroen T. B. M. Tolboom, Liesbeth Dekking, Wouter Koudstaal, Jaap Goudsmit, Katarina Radošević · 2015 · Vaccine
26. Phase II , randomized, open, controlled study of AS 03‐adjuvanted H5N1 pre‐pandemic influenza vaccine in children aged 3 to 9 years: follow‐up of safety and immunogenicity persistence at 24 months post‐vaccination
    Javier Díez‐Domingo, José-Marı́a Baldó, Maria Victoria Planelles‐Catarino, María Garcés‐Sánchez, Isabel Ubeda, Angels Jubert, Josep Marés, Pilar Garcı́a-Corbeira, Philippe Moris, Maurice Teko et al. · 2015 · Influenza and Other Respiratory Viruses
27. Susceptibility to influenza virus infection of bronchial biopsies in asthma
    Ben Nicholas, Sarah Dudley, Kamran Tariq, Peter Hugo Howarth, Kerry Lunn, Sandy Pink, Peter J. Sterk, Ian Michael Adcock, Phillip Monk, Ratko Djukanović · 2017 · Journal of Allergy and Clinical Immunology
28. Computational Approaches and Challenges to Developing Universal Influenza Vaccines
    Xueting Qiu, Venkata R. S. K. Duvvuri, Justin Bahl · 2019 · Vaccines
29. The humanized DRAGA mouse (HLA-A2. HLA-DR4. RAG1 KO. IL-2R g c KO. NOD) establishes inducible and transmissible models for influenza type A infections
    Mirian Mendoza, Devi Gunasekera, Kathleen P. Pratt, Qi Qiu, Sofia A. Casares, Teodor‐D. Brumeanu · 2020 · Human Vaccines & Immunotherapeutics
30. Respiratory virus-induced heterologous immunity
    Emanuel Pusch, Harald E. Renz, Chrysanthi L. Skevaki · 2018 · Allergo Journal International
31. SARS‐CoV‐2 sculpts the immune system to induce sustained virus‐specific naïve‐like and memory B‐cell responses
    Leire de Campos-Mata, Sonia Tejedor Vaquero, Roser Tachó-Piñot, Janet Piñero, E. Grasset, I. Arrieta Aldea, N. Rodrigo Melero, C. Carolis, J. Horcajada, A. Cerutti et al. · 2021 · medRxiv
32. Immune responses to infection with H5N1 influenza virus
    Guus F. Rimmelzwaan, Jacqueline M. Katz · 2013 · Virus Research
33. Toward a Network Model of MHC Class II-Restricted Antigen Processing
    Michael A. Miller, Asha Purnima Veerappan Ganesan, Laurence Crane Eisenlohr · 2013 · Frontiers in Immunology
34. Universal influenza vaccines: a realistic option?
    Rory D. de Vries, Arwen F. Altenburg, Guus F. Rimmelzwaan · 2016 · Clinical Microbiology and Infection
35. Prospects for broadly protective influenza vaccines
    John Jay Treanor · 2015 · Vaccine
36. Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing
    JOHN S. OXFORD · 2013 · British Journal of Clinical Pharmacology
37. A Dominant EV71-Specific CD4+ T Cell Epitope Is Highly Conserved among Human Enteroviruses
    Ruicheng Wei, Chunfu Yang, Mei Zeng, Frances E. Terry, Kai Zhu, Chunhui Yang, Ralf Marius Altmeyer, William D Martin, Anne Searls De Groot, Qibin Leng · 2012 · PLoS ONE
38. A cationic liposome–DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets
    Feng Liu, Xiangjie Sun, Jeff Fairman, David B. Lewis, Jacqueline M. Katz, Min Z. Levine, Terrence M. Tumpey, Xiuhua Lu · 2016 · Virology
39. DNA Vaccines Encoding Antigen Targeted to MHC Class II Induce Influenza-Specific CD8+ T Cell Responses, Enabling Faster Resolution of Influenza Disease
    Laura Lambert, Ekaterina Kinnear, Jacqueline U. McDonald, Gunnveig Grødeland, Bjarne Bogen, Elisabeth Stubsrud, Mona M. Lindeberg, Agnete Brunsvik Fredriksen, John S. Tregoning · 2016 · Frontiers in Immunology
40. Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine
    Annette Fox, Kylie M. Quinn, Kanta Subbarao · 2018 · Drugs
41. A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection
    Takuya Yamamoto, Yuji Masuta, Masatoshi Momota, Masaru Kanekiyo, Tomohiro Kanuma, Shokichi Takahama, Eiko Moriishi, Yasuhiro Yasutomi, Takashi Saito, Barney S. Graham et al. · 2018 · International Immunology
42. Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination
    Shahinul Islam, Fan Zhou, Sarah Larteley Lartey, Kristin Greve-Isdahl Mohn, Florian Krammer, Rebecca Jane Cox, Karl Albert Brokstad · 2019 · Scandinavian Journal of Immunology
43. Distinguishing Causation from Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines
    Wey Wen Lim, Nancy Leung, Sheena G. Sullivan, Eric J. Tchetgen Tchetgen, Benjamin John Cowling · 2019 · American Journal of Epidemiology
44. The Importance of Vaccinating Children and Pregnant Women against Influenza Virus Infection
    Ravi S. Misra, Jennifer Lynn Nayak · 2019 · Pathogens
45. Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results
    Kanchanamala Withanage, Ilse De Coster, Nathalie Cools, Simonetta Viviani, Jessika Tourneur, Marion Chevandier, Manon Lambiel, Paul Willems, Alexandre Le Vert, Florence Nicolas et al. · 2021 · The Journal of Infectious Diseases
46. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection
    Jennifer R. Richardson, Ralph Götz, Vanessa Mayr, Martin J. Lohse, Hans‐Peter Holthoff, Martin Ungerer · 2022 · PLoS ONE
47. Immunopeptidomic analysis of influenza A virus infected human tissues identifies internal proteins as a rich source of HLA ligands
    Ben Nicholas, A.G. Bailey, Karl J. Staples, Tom M. A. Wilkinson, Tim J Elliott, Paul J. S. Skipp · 2022 · PLoS Pathogens
48. Autoimmune VariantPTPN22C1858T Is Associated With Impaired Responses to Influenza Vaccination
    Juliet Crabtree, Wenqian He, Weihua Guan, Mark Flage, Matthew S. Miller, Erik J Peterson · 2016 · The Journal of Infectious Diseases
49. Long-Lasting Mucosal and Systemic Immunity against Influenza A Virus Is Significantly Prolonged and Protective by Nasal Whole Influenza Immunization with Mucosal Adjuvant N3 and DNA-Plasmid Expressing Flagellin in Aging In- and Outbred Mice
    Jorma Hinkula, Sanna Nyström, Claudia Devito, Andreas Bråve, Steven E. Applequist · 2019 · Vaccines
50. Insights into current clinical research on the immunogenicity of live attenuated influenza vaccines
    Исакова-Сивак Ирина Николаевна, Elena Grigorieva, Руденко Лариса Георгиевна · 2020 · Expert Review of Vaccines
51. Comparative Evaluation of the Immune Responses in Cattle Mammary Tissues Naturally Infected with Bovine Parainfluenza Virus Type 3 and Bovine Alphaherpesvirus-1
    Selim Çomaklı, Selçuk Özdemir · 2019 · Pathogens
52. Factors Influencing Microbiota in Modulating Vaccine Immune Response: A Long Way to Go
    Francesca Romana Ponziani, Gaetano Coppola, Pierluigi Rio, Mario Caldarelli, Raffaele Borriello, Giovanni Gambassi, Antonio Gasbarrini, Rossella Cianci · 2023 · Vaccines
53. Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses
    Willemijn F. Rijnink, Daniel Stadlbauer, Eduard Puente‐Massaguer, Nisreen M.A. Okba, Ericka Kirkpatrick Roubidoux, Shirin Strohmeier, Philip A. Mudd, Aaron J. Schmitz, Ali H. Ellebedy, Meagan McMahon et al. · 2023 · Journal of Virology
54. Ex Pluribus Unum: The CD4 T Cell Response against Influenza A Virus
    Caroline M. Finn, Karl Kai McKinstry · 2024 · Cells
55. Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2
    Sydney I. Ramirez, Paul G. Lopez, Farhoud Faraji, Urvi M. Parikh, Amy Heaps, Justin Ritz, Carlee Moser, Joseph J. Eron, David Alain Wohl, Judith S. Currier et al. · 2024 · JCI Insight
56. T cell memory to evolutionarily conserved and shared hemagglutinin epitopes of H1N1 viruses: a pilot scale study
    Venkata R. S. K. Duvvuri, Bhargavi Duvvuri, Veronica Jamnik, Jonathan B. Gubbay, Jianhong Wu, Gillian E. Wu · 2013 · BMC Infectious Diseases
57. Influenza Nucleoprotein Delivered with Aluminium Salts Protects Mice from an Influenza A Virus That Expresses an Altered Nucleoprotein Sequence
    Megan K. L. MacLeod, Alexandria P. David, Niyun Jin, Laura Noges, Jieru Wang, John W. Kappler, Philippa Marrack · 2013 · PLoS ONE
58. Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates
    Jessica A. Flynn, Teresa Weber, Pedro Joel Cejas, Kara S. Cox, Sinoeun Touch, Lauren A. Austin, Yangsi Ou, Michael P. Citron, Bin Luo, Marian E. Gindy et al. · 2022 · Vaccine
59. Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15
    Priyadharshini Devarajan, Allen M. Vong, Catherine H. Castonguay, Noah J. Silverstein, Olivia Kugler‐Umana, Bianca Bautista, Karen A. Kelly, Jeremy Luban, Susan L. Swain · 2023 · Cell Reports
60. Human challenge trials in vaccine development: Strasbourg, September 29 – October 1, 2014
    Rebecca Sheets, Bernard Fritzell, M. Teresa Aguado de Ros · 2015 · Biologicals
61. Norovirus vaccines: Correlates of protection, challenges and limitations
    Nada M. Melhem · 2016 · Human Vaccines & Immunotherapeutics
62. Genomic Circuitry Underlying Immunological Response to Pediatric Acute Respiratory Infection
    Sarah Emily Henrickson, Sasikanth Manne, Douglas V. Dolfi, Kathleen D. Mansfield, Kaela Parkhouse, Rakesh D. Mistry, Elizabeth R. Alpern, Scott E. Hensley, Kathleen E. Sullivan, Susan E Coffin et al. · 2018 · Cell Reports
63. Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza
    Ane Marie Anderson, Marta Baranowska-Hustad, Ranveig Braathen, Gunnveig Grødeland, Bjarne Bogen · 2018 · The Journal of Immunology
64. Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years
    Mai-Chi Trieu, Fan Zhou, Sarah Larteley Lartey, Saranya Sridhar, Siri Mjaaland, Rebecca Jane Cox · 2018 · npj Vaccines
65. FLU-v, a Broad-Spectrum Influenza Vaccine, Induces Cross-Reactive Cellular Immune Responses in Humans Measured by Dual IFN-γ and Granzyme B ELISpot Assay
    Fredrik Oftung, Lisbeth Meyer Næss, Ida Laake, Gregory A. Stoloff, Olga Pleguezuelos · 2022 · Vaccines
66. A nanofiber hydrogel derived entirely from ocean biomass for wound healing
    Tian-Cai Sun, Bing-Yu Yan, Xuchao Ning, Zhi-Yue Tang, Chao Hui, Maozhi Hu, Seeram Ramakrishna, Yun‐Ze Long, Jun Zhang · 2022 · Nanoscale Advances
67. Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection
    Martina Milighetti, Yanchun Peng, Cedric C.S. Tan, Michal Mark, Gayathri Nageswaran, Suzanne Byrne, Tahel Ronel, Tom Peacock, Andreas Mayer, Aneesh Chandran et al. · 2023 · iScience
68. Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
    Claudia Tandler, Jonas S. Heitmann, Tanja Michel, Maddalena Marconato, Simon U. Jaeger, Christian Martin Tegeler, Monika Denk, Marion Richter, Melek Tutku Oezbek, Yacine Maringer et al. · 2023 · International Journal of Infectious Diseases
69. Assessment of CD8+ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study
    Thomas G. Evans, Flora Castellino, Monika Kowalik Dobczyk, Gwen Tucker, Ana Marie Walley, Katrin Van Leuven, Jelle Klein, Kathryn Tucker Rutkowski, Chris Ellis, Elizabeth Eagling-Vose et al. · 2024 · The Lancet Microbe
70. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65–85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial
    Joseph Eiden, Carlos A. Fierro, Alexander White, Matthew Davis, Margaret Rhee, Mark A. Turner, Bryan J. Murray, Renee Herber, Roger Aitchison, David C. Marshall et al. · 2024 · The Lancet Infectious Diseases
71. Cytomegalovirus vaccine vector-induced effector memory CD4 + T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge
    Daniel Malouli, Meenakshi Tiwary, Roxanne M. Gilbride, David W. Morrow, Colette M. Hughes, Andrea N. Selseth, Toni Penney, Priscila M. S. Castanha, Megan Wallace, Yulia Yeung et al. · 2024 · Nature Communications
72. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5–7 May 2014
    Nancy J. Cox, Julian Hickling, Rebecca Jones, Guus F. Rimmelzwaan, Linda C. Lambert, John W. Boslego, Руденко Лариса Георгиевна, Leena Yeolekar, James S. Robertson, Joachim Hombach et al. · 2015 · Vaccine
73. The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine
    Jack A Panapasa, Rebecca Jane Cox, Kristin Greve-Isdahl Mohn, Lara A. Aqrawi, Karl Albert Brokstad · 2015 · Human Vaccines & Immunotherapeutics
74. Perspectives on vaccine development for the elderly
    Ernesto Oviedo‐Orta, Chris Ka-fai Li, Rino Rappuoli · 2013 · Current Opinion in Immunology
75. Adaptive evolution of a novel avian-origin influenza A/H7N9 virus
    Ramaiah Arunachalam · 2014 · Genomics
76. Controlled human infections
    Meta Roestenberg, Annie X.Y. Mo, Peter G. Kremsner, Maria Yazdanbakhsh · 2017 · Vaccine
77. Early programming and late‐acting checkpoints governing the development of CD 4 T‐cell memory
    Kunal Dhume, Karl Kai McKinstry · 2018 · Immunology
78. Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza
    Meito Shibuya, Shigeyuki Tamiya, Atsushi Kawai, Toshiro Hirai, Mark Steven Cragg, Yasuo Yoshioka · 2021 · iScience
79. A Novel Neuraminidase Virus-Like Particle Vaccine Offers Protection Against Heterologous H3N2 Influenza Virus Infection in the Porcine Model
    Vasilis C. Pliasas, Zach Menne, Virginia Aida, Ji‐Hang Yin, Maria C. Naskou, Peter J. Neasham, J. Fletcher North, Dylan Wilson, Katharine A. Horzmann, Joshy Jacob et al. · 2022 · Frontiers in Immunology
80. Vaccination with the Recombinant Major Outer Membrane Protein Elicits Antibodies to the Constant Domains and Induces Cross-Serovar Protection against Intranasal Challenge with Chlamydia trachomatis
    Delia F. Tifrea, Pooja Ralli-Jain, Sukumar Pal, Luis M. de la Maza · 2013 · Infection and Immunity
81. Partial Protection against Porcine Influenza A Virus by a Hemagglutinin-Expressing Virus Replicon Particle Vaccine in the Absence of Neutralizing Antibodies
    Meret E. Ricklin, Nathalie Jane Vielle, Sylvie Python, Daniel Brechbühl, Béatrice Zumkehr, Horst Posthaus, Gert Zimmer, Artur Summerfield · 2016 · Frontiers in Immunology
82. Host immune response–inspired development of the influenza vaccine
    Angela Choi, Adolfo García‐Sastre, Michael Schotsaert · 2020 · Annals of Allergy Asthma & Immunology
83. Robust hepatitis B vaccine-reactive T cell responses in failed humoral immunity
    Gounwa Awad, Toralf Roch, Ulrik Stervbo, Sviatlana Kaliszczyk, Anna Stittrich, Jan H. Hörstrup, Ocan Cinkilic, Heiner Appel, Л.В. Натрус, Ludmila Gayova et al. · 2021 · Molecular Therapy — Methods & Clinical Development
84. Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs
    Eleni Vatzia, Elizabeth R. Allen, Tanuja Manjegowda, Susan Jane Morris, Adam McNee, Veronica Martini, Reshma Kaliath, Marta Ulaszewska, Amy C. Boyd, Basudev Paudyal et al. · 2021 · Frontiers in Immunology
85. Hemagglutinin-specific CD4 + T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans
    Shuguang Tan, Shihong Zhang, Bin Wu, Yingze Zhao, Wei Zhang, Min Han, Ying Wu, Guoli Shi, Yingxia Liu, Jinghua Yan et al. · 2017 · Vaccine
86. Human influenza: Pathogenesis, clinical features, and management
    Frederick G. Hayden, Menno D. de Jong · 2013
87. Long-persisting SARS-CoV-2 spike-specific CD4+ T cells associated with mild disease and increased cytotoxicity post COVID-19
    Guihai Liu, Elie Antoun, Anastasia Fries, Xuan Yao, Zixi Yin, Danning Dong, Wenbo Wang, Peter A. C. Wing, Wanwisa Dejnirattisa, Piyada Supasa et al. · 2025 · Nature Communications
88. Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections
    Z. Zhuang, Jianfen Zhuo, Yaochang Yuan, Zhaoming Chen, Sheng-Nan Zhang, Ai-Ru Zhu, Jing-Xian Zhao, Jin-Cun Zhao · 2024 · Vaccines
89. Evaluation of In Vitro Cross-Reactivity to Avian H5N1 and Pandemic H1N1 2009 Influenza Following Prime Boost Regimens of Seasonal Influenza Vaccination in Healthy Human Subjects: A Randomised Trial
    Delia Bethell, David Saunders, Anan Jongkaewwattana, Jarin Kramyu, Thitithayanont Arunee, Suwimon Wiboon-ut, Kosol Yongvanitchit, Amporn Limsalakpetch, Utaiwan Kum-Arb, Nichapat Uthaimongkol et al. · 2013 · PLoS ONE
90. Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin
    So‐Yoon Won, Kristin Hunt, Hannah Guak, Benedeta Hasaj, Nathalie Charland, Nathalie Landry, Brian J. Ward, Connie M. Krawczyk · 2018 · Vaccine
91. Immunité adaptative contre le virus SARS-CoV-2
    Béhazine Combadière · 2020 · médecine/sciences
92. Antibody Responsiveness to Influenza: What Drives It?
    Xia Lin, Fangmei Lin, Tingting Liang, Mariette Ducatez, Mark Zanin, Sook‐San Wong · 2021 · Viruses
93. Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults
    Joseph E. Eiden, Gilad Gordon, Carlos A. Fierro, Renee Herber, Roger Aitchison, Robert B. Belshe, Harry B. Greenberg, Daniel Fredric Hoft, Yasuko Hatta, Michael J. Moser et al. · 2021 · Vaccines
94. Antigen presenting cells: Professionals, amateurs, and spectators in the 'long game' of lung immunity
    Kerrie E Hargrave, Megan K. L. MacLeod, Julie C. Worrell · 2022 · The International Journal of Biochemistry & Cell Biology
95. Influenza Virus Specific CD8+T Cells Exacerbate Infection Following High Dose Influenza Challenge of Aged Mice
    Elizabeth M. Parzych, Lauren J. DiMenna, B. P. Latimer, Juliana C. Small, Senthil Kannan, Brian Manson, Marcio O. Lasaro, E. John Wherry, Hildegund C.J. Ertl · 2013 · BioMed Research International
96. Impact of Distinct Poxvirus Infections on the Specificities and Functionalities of CD4+T Cell Responses
    Nicholas Anthony Siciliano, Adam R. Hersperger, Aimee Lacuanan, Ren-Huan Xu, John Sidney, Alessandro Sette, Luis J. Sigal, Laurence Crane Eisenlohr · 2014 · Journal of Virology
97. T‐cell responses against rhinovirus species A and C in asthmatic and healthy children
    Cibele Marina Gaido, Caitlyn M. Granland, Ingrid A. Laing, Peter Neils Le Souëf, Wayne Robert Thomas, Andrew J Currie, Belinda J. Hales · 2017 · Immunity Inflammation and Disease
98. Single-Cell Tracking Reveals a Role for Pre-Existing CCR5+ Memory Th1 Cells in the Control of Rhinovirus-A39 After Experimental Challenge in Humans
    Lyndsey M. Muehling, Ronald B. Turner, Kenneth B Brown, Paul W. Wright, James T. Patrie, Sampo J. Lahtinen, Markus J. Lehtinen, William W. Kwok, Judith A. Woodfolk · 2017 · The Journal of Infectious Diseases
99. Pathogen Recognition by CD4 Effectors Drives Key Effector and Most Memory Cell Generation Against Respiratory Virus
    Priyadharshini Devarajan, Michael C. Jones, Olivia Kugler‐Umana, Allen M. Vong, Jingya Xia, Susan L. Swain · 2018 · Frontiers in Immunology
100. Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine
     Ki‐Hye Kim, Young‐Man Kwon, Young‐Tae Lee, Hye Suk Hwang, Min‐Chul Kim, Eun‐Ju Ko, Bao‐Zhong Wang, Fu‐Shi Quan, Sang‐Moo Kang · 2018 · Virology